Non–Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection

Similar Items

• Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction
  od: Covert, Courtney, i dr.
  Izdano: (2019)
• Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction
  od: Kahn, Jessica A., i dr.
  Izdano: (2012)
• Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction
  od: Widdice, Lea E., i dr.
  Izdano: (2019)
• Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community
  od: Kahn, Jessica A., i dr.
  Izdano: (2016)
• Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus among 13–26 Year-Old Young Men after HPV Vaccine Introduction
  od: Chandler, Emmanuel, i dr.
  Izdano: (2018)